Core Viewpoint - The announcement regarding the insider trading investigation of Jiang Wei, a major shareholder and actual controller of Haohai Biological Technology Co., Ltd., has raised concerns among investors about the company's future, despite the company's claims that the incident is unrelated to its operations [1][2]. Group 1: Company Background - Haohai Biological Technology was founded in 2007 and has evolved into a technology-driven enterprise engaged in the research, production, and sales of medical devices and pharmaceuticals, focusing on aesthetic medicine and wound care, ophthalmology, and orthopedic products [5]. - The company was listed on the Hong Kong Stock Exchange in April 2015 and later on the Shanghai Stock Exchange's Sci-Tech Innovation Board in October 2019 [5]. Group 2: Shareholder Structure - Jiang Wei and You Jie are the controlling shareholders, holding 28.53% and 17.29% of the shares, respectively, making them the first and second largest shareholders [3]. - Jiang Wei is also the ultimate beneficiary of a partnership that holds 1% of the company's shares, indicating a significant influence over the company's governance [3]. Group 3: Financial Performance - In 2024, Haohai Biological reported revenue of 2.698 billion yuan, a mere 1.64% increase compared to previous years, indicating a significant slowdown in growth [5]. - The company experienced a decline in revenue and net profit in the first half of 2025, with revenue dropping by 7.12% to 1.304 billion yuan and net profit decreasing by 10.29% to 211 million yuan [6]. - The three main business segments—medical aesthetics, ophthalmology, and orthopedics—saw revenue declines of 9.31%, 18.61%, and 2.58%, respectively, in the first half of 2025 [6]. Group 4: Management and Strategy - The company's operational management is handled by a professional team led by key figures such as Hou Yongtai and Wu Jianying, who hold significant positions within the company [3]. - The company has reported a 21.53% decrease in R&D expenses, with the R&D expense ratio falling to 7.54% from 8.93% in the previous year, attributed to the completion of core projects [6].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年9月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 ...

智通财经APP讯，昊海生物科技(06826)发布公告，于2025年9月17日，该公司斥资51.52万港元回购1.84 万股。 ...

昊海生物科技(06826)发布公告，于2025年9月17日，该公司斥资51.52万港元回购1.84万股。 ...

格隆汇9月17日丨昊海生物科技(06826.HK)发布公告，2025年9月17日耗资51.52万港元回购1.84万股，回 购价格每股28港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2025年9月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 ...

红星资本局9月17日消息，玻尿酸巨头昊海生科（688366.SH）昨日晚间公告称，公司控股股东、实际控制人之一蒋伟收到中国证监会出具的《行政处罚事 先告知书》，处罚的原因为涉嫌内幕交易。 昊海生科强调，此次处罚是针对蒋伟个人，涉及的事项与公司无关。 据了解，昊海生科虽然由蒋伟创立，但其本人长期退居幕后，几乎不参与公司经营。不过，蒋伟设立的股权体系使之牢牢掌握昊海生科的控制权，上市6年 间，蒋伟从昊海生科获得分红超2.5亿元。 9月17日，红星资本局拨打昊海生科董秘办电话，但截至发稿未能接通。此前，昊海生科董事长侯永泰在接受采访时表示，蒋伟就是一个投资人，喜欢做股 票，但操作的并不是昊海生科的股票。 资料图 图据视觉中国 资料显示，昊海生科是一家专注于研发、生产及销售医用生物材料的高科技生物医药企业，系国内知名的玻尿酸生产商。 昊海生科最早起源于蒋伟创立的昊海有限。2007年5月，上海华源松江分公司相关资产被注入到昊海有限，为该公司进入玻尿酸领域打下基础，侯永泰也是 此时和蒋伟产生联系。2009年，侯永泰接任昊海有限董事长职位，并一直持续至今，而蒋伟退居幕后，再未在公司任职。 2019年，昊海生科登陆上交所，此 ...

Group 1 - The Ministry of Commerce and eight other departments issued 19 specific measures to expand service consumption, focusing on enhancing service quality and promoting consumer activities [1] - The "Service Consumption Quality Improvement and Benefit Action" plan was introduced to strengthen policy support, build platforms, and optimize the consumption environment [1] - The initiative includes the continuous development of the "Buy in China" brand and the launch of a series of promotional activities in key service sectors [1] Group 2 - The Chinese Ministry of National Defense confirmed that the Fujian aircraft carrier is conducting sea trials, which is a normal part of its construction process [2] - The development of the aircraft carrier is aligned with national security needs and technological advancements, emphasizing China's commitment to a defensive national policy [2] - The Fujian carrier is expected to play a significant role in safeguarding national sovereignty and development interests [2] Group 3 - The China National Medical Products Administration released the first industry standard for medical devices using brain-computer interface technology, set to take effect on January 1, 2026 [4] - This standard aims to support the high-quality development of the brain-computer interface medical device industry [4] Group 4 - The Shenzhen Securities Regulatory Bureau issued a warning letter to Qianhai Hongtai Fund Management Co., Ltd. for failing to complete fund filing procedures after fundraising [5] - This action is based on violations of the Private Fund Management Regulations [5] Group 5 - Vanke A received a loan of up to 2.064 billion yuan from Shenzhen Metro Group [8] - Hengwei Technology plans to acquire 75% of Shuheng Technology's shares, leading to a stock suspension [8] - Shanghai Construction's stock has seen significant short-term gains, indicating potential market overheating [8] - Huohai Biotechnology's controlling shareholder received an administrative penalty notice [8] - Funeng Technology plans to mass-produce its third-generation semi-solid battery by 2026 [8] - Luxiao Technology signed an AI robot cooperation agreement with its subsidiary [8] - Haon Electric received a product designation notice, estimating total revenue of approximately 2.477 billion yuan over its lifecycle [8] - Haowei Group has entered NVIDIA's supply chain [8] - AVIC Optoelectronics has shipped UQD connectors and liquid cooling pipe components to overseas manufacturers [8]

Group 1 - The core point of the article is that Haohai Biological Technology has received a notice from the China Securities Regulatory Commission regarding an administrative penalty, which pertains to its controlling shareholder Jiang Wei, and is unrelated to the company's operations [1] - The company stated that Jiang Wei does not participate in daily management, and the matter will not have a significant impact on the company's daily operations, business, or financials [1]

每经记者｜陈晴 每经编辑｜程鹏 张喜威 王晓波 ~~~文末有福利~~~ 标题点睛： 9月16日，有消息称，在长春航展现场两架小鹏汇天eVTOL（电动垂直起降器）相撞后坠机。对此，小鹏汇天方面回应称："9月16日下午，广东汇天通航 在长春航展预演结束后，参与双机编队演练的两架飞行器因飞行间距不足发生接触。 1 隔夜市场 美股三大指数集体收跌，道指跌0.27%，标普500指数跌0.13%，纳斯达克综合指数跌0.07%；大型科技股涨跌互现，特斯拉涨超2%，甲骨文涨超1%，微 软、英伟达跌超1%。中概股多数上涨，纳斯达克中国金龙指数涨1.76%，创下自2022年2月以来新高；蔚来涨超8%，百度涨超7%，京东、爱奇艺涨超 3%，阿里巴巴涨超2%。 国际贵金属期货收盘涨跌不一，COMEX黄金期货涨0.23%，报3727.5美元/盎司；COMEX白银期货跌0.19%，报42.88美元/盎司。 国际油价强势上扬，美油主力合约收涨1.97%，报64.55美元/桶；布伦特原油主力合约涨1.59%，报68.51美元/桶。 欧洲三大股指收盘全线下跌，德国DAX指数跌1.77%报23329.24点，法国CAC40指数跌1%报7818. ...